D-Y. Oh

1.2k total citations
60 papers, 745 citations indexed

About

D-Y. Oh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, D-Y. Oh has authored 60 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 23 papers in Surgery. Recurrent topics in D-Y. Oh's work include Gastric Cancer Management and Outcomes (23 papers), Colorectal Cancer Treatments and Studies (14 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers). D-Y. Oh is often cited by papers focused on Gastric Cancer Management and Outcomes (23 papers), Colorectal Cancer Treatments and Studies (14 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers). D-Y. Oh collaborates with scholars based in South Korea, United States and Spain. D-Y. Oh's co-authors include Tae‐Yop Kim, S-A Im, Kyung-Woo Lee, Y-J. Bang, Mina Kim, Seung Woo Han, S.R. Park, Hong Song, W H Kim and Takeshi Omori and has published in prestigious journals such as Cancer Research, British Journal of Cancer and Annals of Oncology.

In The Last Decade

D-Y. Oh

53 papers receiving 741 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D-Y. Oh South Korea	14	496	388	237	116	101	60	745
Eliana Amato Italy	12	405 0.8×	189 0.5×	201 0.8×	21 0.2×	251 2.5×	14	716
Terence Tan Singapore	11	447 0.9×	332 0.9×	607 2.6×	15 0.1×	120 1.2×	25	1.1k
Yusuke Tomita Japan	14	80 0.2×	348 0.9×	367 1.5×	14 0.1×	162 1.6×	40	689
Kara L. Hamilton‐Nelson United States	15	146 0.3×	269 0.7×	158 0.7×	13 0.1×	226 2.2×	33	649
Florian Ehehalt Germany	16	363 0.7×	51 0.1×	420 1.8×	16 0.1×	265 2.6×	26	837
Gokce Askan United States	13	469 0.9×	128 0.3×	365 1.5×	7 0.1×	149 1.5×	25	717
Rong‐Liang Shi China	15	142 0.3×	95 0.2×	73 0.3×	6 0.1×	138 1.4×	28	431
Eugenio Taboada United States	10	157 0.3×	199 0.5×	83 0.4×	4 0.0×	159 1.6×	22	538
Sari Tuupanen Finland	16	164 0.3×	48 0.1×	83 0.4×	19 0.2×	361 3.6×	33	756
Daniel O. Kechele United States	13	159 0.3×	37 0.1×	95 0.4×	9 0.1×	213 2.1×	18	487

Countries citing papers authored by D-Y. Oh

Since Specialization

Citations

This map shows the geographic impact of D-Y. Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D-Y. Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D-Y. Oh more than expected).

Fields of papers citing papers by D-Y. Oh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D-Y. Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D-Y. Oh. The network helps show where D-Y. Oh may publish in the future.

Co-authorship network of co-authors of D-Y. Oh

This figure shows the co-authorship network connecting the top 25 collaborators of D-Y. Oh. A scholar is included among the top collaborators of D-Y. Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D-Y. Oh. D-Y. Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, J-Y., Funda Meric‐Bernstam, Ana Oaknin, et al.. (2025). 145P Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. Annals of Oncology. 36. S251–S252. 1 indexed citations

Oh, D-Y., Min‐Hee Ryu, Emiliano Calvo, et al.. (2024). 656P Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results. Annals of Oncology. 35. S518–S518.

Janjigian, Y. Y., Hanneke W.M. van Laarhoven, Sun Young Rha, et al.. (2024). 1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03). Annals of Oncology. 35. S878–S878. 11 indexed citations

O’Kane, Grainne M., Jennifer L. Spratlin, D-Y. Oh, et al.. (2024). 44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy. Annals of Oncology. 35. S22–S22. 1 indexed citations

Park, Won, Eileen M. O’Reilly, Li Cp, et al.. (2024). 1532TiP Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study. Annals of Oncology. 35. S934–S934. 1 indexed citations

Halperin, Daniel M., Sten Myrehaug, Pamela L. Kunz, et al.. (2024). 211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study. Annals of Oncology. 35. S92–S93. 4 indexed citations

Oh, D-Y., Han Sun, Jae‐Weon Kim, et al.. (2024). 134O Asia subgroup overall survival and long-term follow-up results of the phase IIb HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC). Annals of Oncology. 35. S1453–S1453. 1 indexed citations

Moehler, Markus, D-Y. Oh, Kazuyoshi Kato, et al.. (2024). 397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305. Annals of Oncology. 35. S160–S161. 7 indexed citations

Cruz‐Correa, Marcia, D-Y. Oh, Ken Kato, et al.. (2024). 1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up. Annals of Oncology. 35. S893–S894. 4 indexed citations

10.

Meric‐Bernstam, Funda, Yoichi Naito, Stéphanie Gaillard, et al.. (2024). 606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors. Annals of Oncology. 35. S485–S486. 7 indexed citations

11.

Li, Bob T., Funda Meric‐Bernstam, Aditya Bardia, et al.. (2023). 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Annals of Oncology. 34. S459–S460. 19 indexed citations

12.

Meric‐Bernstam, Funda, Vicky Makker, Ana Oaknin, et al.. (2023). LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. Annals of Oncology. 34. S1273–S1274. 3 indexed citations

13.

Oh, D-Y., H-T. Arkenau, Josep Tabernero, et al.. (2023). 139MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology. 34. S1526–S1527. 3 indexed citations

14.

Lee, Kyung-Woo, Minkyu Jung, Jieer Ying, et al.. (2023). 1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study. Annals of Oncology. 34. S855–S856. 6 indexed citations

15.

Oh, D-Y., Ken Kato, Tobias Arkenau, et al.. (2023). LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology. 34. S1320–S1321. 6 indexed citations

16.

Oh, D-Y., et al.. (2022). 57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC). Annals of Oncology. 33. S566–S567. 2 indexed citations

17.

Oh, D-Y., Filippo de Braud, John Bridgewater, et al.. (2020). 79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. Annals of Oncology. 31. S271–S272. 4 indexed citations

18.

Boku, Narikazu, M.-H. Ryu, D-Y. Oh, et al.. (2020). LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Annals of Oncology. 31. S1192–S1192. 80 indexed citations

19.

Oh, D-Y., Tobias Arkenau, María Alsina, et al.. (2020). 439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC). Annals of Oncology. 31. S428–S428. 1 indexed citations

20.

Oh, D-Y., et al.. (2004). Molecular cloning, pharmacological characterization, and histochemical distribution of frog vasotocin and mesotocin receptors. Journal of Molecular Endocrinology. 33(1). 293–313. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact